



Money
or Down Markets

Make
In Up

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Charles Moskowitz Michael King

August 7, 2017

Market Strategies Guide to Successful Trading

**To subscribe to the Options Only Account Trades
Simply TEXT the word TRADES to the Number
and you will automatically be included.**

Market Strategies \$10,000 Options Account

Funds in Use \$ 350.00

Gain on closed Trades \$ 466.00

YTD: \$ 11,088.00

Long 10 BBRY August 9.50 Calls

MARKET LETTER INDEX	PG
Charles Moskowitz Discussion	1
\$10,000 Options Account	2
New Stock and Option Recommendations	2
Technical Information	3
Market Laboratory	3
Stock Positions 100,000 Acct	4
Week's Economic Numbers, Earnings Releases & Media Data	6
Fundamentals	7
Economics	9
Cycles	13
July Calendar	15
Lower Cap Stocks to Buy	16
Fundamental Stocks to Buy	20

Charles Moskowitz Discussion

Week 31 was a gain of \$466 again achieving another new high in the YTD gains at \$11,088. We have only one open position in BBRY 9.50 calls that require \$350 to carry. All of the gains this week were from SPY trades, and again I will explain that with volatility being so low, these are priced below their normal premiums, allowing use to take positions that can benefit from moves as small as \$. 50-.75 swings in the ETF.

This week was interesting in that we had some major rotation and divergences. The DJIA forged higher and now has a run of 9 up days 8 of which were new record closes,

While the NASDAQ has not been able to regain the close on the "reversal day" of last Thursday (7/27), the Transports over the same time frame of the Dow are down almost 5% and from the new high, over 6.5%. They have bounced off the 200 day moving average at 9110. These moves in different directions are not uncommon for short periods of time, but up 2.7% vs. down 5% (transports) are fairly excessive. Now the Dow 30 are overbought while the transports are deeply oversold while the QQQ's are just neutral. The A.A.I.I. sentiment numbers show a big gain in bears and a small gain in bulls with the neutrals making a decision to get into the bear camp. While this is a contrary indicator, they do get it right every so often. Even the odd-lot shorts got it right for short periods of time for some big gains.

The interesting happenstance for the week was that politics, both nationally and internationally had little impact on the markets. With the notable exception of the selloff on Mueller forming a grand jury on Russia. Even that was short lived.

The markets have no sympathy for earnings misses; or even beats, both top and bottom line that come with poor guidance. The best example was VIAB, which easily beat on Thursday and traded up \$1.33 (in the after-hours around 36) only to issue poor guidance on ad revenues and gap down 3 and then continue down to \$30.22 -4.85 or almost 14%. This is what priced to perfection means.

In contrast, BA moved from \$212 to 246 on its earnings last week. I mention this because I want to bring your attention on pages 20 and 21 the fact that Mike puts out a fundamentally based list of stock, that have nothing to do with my options trading, but nonetheless produces strong gains. Again, BA as an example, Mike was a buyer @ \$132, and has raised stops on the way up. Again, Options is trading, Fundamental is investing. It is certainly worth a look.

I will continue to look for trades in both common stocks and ETFs that show as little risk and optimum rewards...If you have portfolios of longer term holdings you should be buying some protection. It's cheap and I believe necessary. **CAM**

All trades were based on your participation in the texting service to receive updates.

DATE		PRICE	COST	PROCEEDS	RESULTS
08/04	Sold 10 SPY August 4 th 247 Calls	0.28		280	\$ 120 Gain
08/04	Bought 10 SPY August 4 th 247 Calls	0.16	160		
08/03	Sold 10 SPY August 4 th 247 Calls	0.51		510	\$ 100 Gain
08/03	Bought 10 SPY August 4 th 247 Calls	0.41	410		
08/02	Sold 5 SPY August 4 th 247 Puts	0.68		340	\$ 100 Gain
08/02	Sold 5 SPY August 4 th 247 Puts (100 % Profit Rule)	0.96		480	\$ 240 Gain
08/02	Bought 10 SPY August 4 th 247 Puts	0.48	480		
08/02	Sold 10 SPY August 4 th 247.50 Calls	0.53		530	\$ 80 Gain
07/31	Bought 10 BBRY Aug 9.50 Calls	0.35	350		
07/31	Sold 6 LUV August 60 Calls (50% Loss Rule)	0.28		168	\$ 174 Loss
07/31	Bought 10 SPY August 4 th 247.50 Calls	0.45	450		
07/27	Bought 6 LUV August 60 Calls	0.57	342		

NEW TRADES OPTIONS ACCOUNT

(1) BUY 10 ADM 8/ \$42 CALLS @ \$0.66
(2) BUY 15 SKYW 9/\$ 40 CALLS @ \$0.30

NEW TRADES \$ 100 000 ACCOUNT:
(1) BUY 20 ADM 8/ \$42 CALLS @ \$ 0.66
(2) BUY 30 SKYW 9/ 40 CALLS @ \$0.30

MARKET LABORATORY - WEEKLY CHANGES

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect

Dow 22,092.81 +262.50 +1.20%	Nasdaq 6351.56 -23.11 -0.36%	S&P 500 2476.83 +4.73 +0.19%	Transportation 9277.63 +50.56 +0.55%	Russell 2000 1412.32 -16.94 -1.19%	Nasdaq100 5899.91 -9.01 -0.15%
Gold (spot) 1258.30 -10.10 -0.8%	Silver Sept 16.252 -0.205 -1.2%	Crude July 49.58 -0.13 -0.3%	Heating Oil 1.6468 +0.0059 +0.4%	Unleaded Gas 1.6463 +0.0041 +0.1%	Natural Gas 2.774 -0.167 -5.7%
VIX 10.03 -0.26 -2.5%	Put/Call Ratios S&P 100 85/100's -22/100's	Put/Call Ratios CBOE Equity 68/100's -4/100's	Bonds 154-03 +0-29 2.897%0-05.4%	10 Yr. Note 125-30 +0-6 2.29%-0305%	Copper 2.7225 +0.310 +11.5%
CRB Inflation Index 180.68 -1.44 -0.8%	Barron's* Confidence 74.1 -1.9	S&P100 1095.42 +5.89 +0.54%	5 YR Note 117-27 -0+11 1.84%-0.025%	Dollar 93.49 +0.23 +0.25%	DJ Utilities 731.87 +7.81 +1.08%
AAll Confidence Index Average	Bullish 36.1% +1.6% 38.4%	Bearish 32.1% +7.8% 30.30%	Neutral 31.8% -9.4% 30.96%	M1 Money Supply +9.25% July 24 th	M2 Money Supply +5.31% July 24 th

Prices are copied from Barron's Weekly and Yahoo Finance and may be incorrect * Component Change is in the Confidence Index

SUPPORT

RESISTANCE

S&P 500	2434	2500
NASDAQ (QQQ)	140.01	146.40
Trans	9000	9520
DOW	21,350	22,180
TLT	122.20	126.80

Each Stock is allocated a theoretical \$ 5,000 share of the portfolio

	Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/(\$ 920Los)
BBRY 400	11.21	06/07			
GLYC 400	12.66	06/01			
HL 500	5.72	06/01			
GSAT 1500	2.30	05/18			
SLV 300	15.78	05/15			
AGQ 150	40.39	04/07			
NUGT 75	35.68	03/13			
RWM 100	50.60	11/21			
SPXU 200	22.88	11/14			
AMBA 100	63.75	10/13			
MOS 200	27.53	05/02			
EYES 500	5.04	04/04			
EYES 1000	6.49	12/28			
TWTR 200	28.51	10/28			
MOS 100	43.55	08/14			
HL 500	3.95	05/03			
SAN 600	8.40	12/16			
TEXQY 200	6.56	7/11			
REPR* 5000	0.22	10/22/12			

Recommendations will be both listed in this letter and texted to members. Previous closed out trades can be seen on each preceding weekly market letter. X means stop loss

July24th;17th;10th;3rd;June26th;19th;12th;5th;May9th;22nd;15th;8th;1st;Aprilth;24th;17th;10th;3rd;March7th;20th;13th;6th

SCO means stop close only

Additional New Options Trades: will be texted

Large Account: Additional trades and stop losses will be Texted and E-Mailed

The new number has been provided. Call Dave Rodgers if there are problems at (832) 236- 3640.

Or Mike King 702 650 3000; Charles Moskowitz 617 827 1296

There were six closed out options positions last week gaining \$ 932.00 in options trading. There were no closing stock trades: There is one remaining long option position, the 20 BBRY August \$9.50 Calls bought at \$ 0.35 costing \$700.00. The net gain for the week was \$ 932.00. The total margin requirement for options is \$ 700.00. The options expire on the third Friday of each Month unless otherwise posted. The Stock table has the following 19 positions: AGQ, BBRY,EYES (2), GLYC, GSAT,HL(2), MOS (2), NUGT, REPR, RWM, SAN, SCO,SLV, SPXU TEXQY, TWTR,

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically. Money management is based on a hypothetical \$100,000.00.

The 19 stock positions would cost \$79,338.00. The open long options position; the BBRY August \$9.50 Calls require \$700.00; when combined with the stock requirement of \$79,338.00 equals \$80,038.00 which leaves excess cash of \$19,962.00.

YEAR TO DATE the \$100,000 Account has had 148 closed out trades between stocks, options and covered writes versus stock positions. Of those, 101 were gains and 47 were losses. Gains to date equal \$53,215.00; losses equal \$18,689.00, for a net gain of \$34,526.00. This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors. The trading is hypothetical and we do not count commission costs.

Previous Week's Recommendations and Rules for the \$ 100,000 account

- **Text UPDATES to number provided**
- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated.
- When the option has doubled sell half the position.
- Stop Loss protection is half if Option trades above 50 Cents or offered with each trade.
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price
- Subscribers can follow us on Twitter or call 702 650 3000 for up to date information.

Note: Closed out stock and option positions can be found in previous weekly market letters: Such as

July 31st; July 24th; 17th; 10th; 3rd; June 26th; 19th; 12th; 5th; May 29th; 22nd; 15th; 8th; 1st; April 24th; 17th; 10th; 3rd

Option	COST	Date	Sold	Date	Profit/(Loss)
SPY Aug4th 247 20 lots	<u>Calls</u> <u>0.16</u>	08/04/17	0.28	08/04/2017	\$ 240
SPY Aug4 th 247.00 20 lots	<u>Puts</u> <u>0.48</u>	08/02/17	0.96 (sold Half on 100% profits rule) 0.68 sold Balance	08/02/2017 08/02/2017	\$ 480 \$ 200
SPY Aug4th 247 20 lots	<u>Calls</u> <u>0.41</u>	08/03/17	0.51	08/03/2017	\$ 200
BBRY Aug9.50 20 lots	<u>Calls</u> <u>0.35</u>	07/31/17			
SPY Aug 4 th 247.50 20 lots	<u>Calls</u> <u>0.45</u>	07/31/17	0.53	08/02/2017	\$ 160
LUV Aug 60 12 lots	<u>Calls</u> <u>0.57</u>	07/27/17	0.28 (50% Loss Rule)	07/31/2017	(\$ 348)

This week's Economic Numbers and Earnings Releases: Before the Open on top of the Row; After the Close below the Economics information and News releases: Space is limited:

MONDAY	<p>CNA Financial CNA (0.76 vs 0.77) DANA Inc DAN (0.51 vs 0.53) Mercury General MCY (0.50 vs 0.88) Roper ROP (2.22 vs 1.56) Sanofi SNY (1.30)</p> <p>09:45 hrs Chicago PMI July (60 vs 65.7) 10:00 hrs Pending Home Sales June (1.1% vs -0.8%)</p> <p>Altaba AABA (0.15 vs 0.09) Amkor AMKR (0.12 vs 0.02) Green Plains GPRE (-0.06 vs 0.21) Healthsouth HLS (0.68 vs 0.69) Olin OLN (0.19 vs 0.24) Owens-Illinois OI (0.67 vs 0.65) Pandora P (-0.24 vs -0.12) Silicon Motion SIMO (0.72 vs 0.86)</p>
TUESDAY	<p>Air Products APD (1.59 vs 1.92) Archer-Daniels ADM (0.52 vs 0.41) BP 0.05 vs 0.23 Cummins CMI (2.56 vs 2.40) Eaton ETN (1.16 vs 1.07) Ecolab ECL (1.12 vs 1.08) Emerson EMR 0.68 vs 0.80 Fresenius Medical FMS (1.05 vs 0.96) Honda HMC 88.87 vs 96.93) IGT (0.32 vs 0.43) Pfizer PFE 0.66 vs 0.64 Phillips 66 PSX (1.03 vs 0.94) Sony SNE (56.17 vs 16.44) Sprint S (-0.05 vs -0.08) Xerox XRX (0.80 vs 0.26)</p> <p>08:30 hrs Personal Income June (0.3% vs 0.4%) 08:30 hrs Personal Spending June (0.1% vs 0.1%) 08:30 hrs PCE Prices - CORE June (NA vs -0.1%) 10:00 hrs Construction Spending June (0.5% vs 0.0%) 10:00 hrs ISM Index July (56.2 vs 57.8) 14:00 hrs Auto Sales July (NA vs 4.27MlnUnits) 14:00 hrs Truck Sales July (NA vs 8.77Mln Units)</p> <p>Apple AAPL (1.57 vs 1.42) Assurant AIZ (1.60 vs 1.42) Community Health CYH (-0.02 vs 0.09) DaVita DVA 0.93 vs 1.01 Devon Energy DVN 0.33 vs 0.06 EOG EOG 0.11 vs -0.38 Hanesbrands HBI 0.53 vs 0.51 Ternium TX 1.04 vs 0.78 Voya Financial VOYA 0.85 vs 0.79</p>
WEDNESDAY	<p>AutoNation AN (0.98 vs 1.08) Bunge BG (0.16 vs 0.79) Cardinal Health CAH 1.25 vs 1.14 Delphi Auto DLPH (1.65 vs 1.59) Dominion Energy D (0.67 vs 0.71) Humana HUM 3.08 vs 2.30 Molson Coors TAP (2.10 vs 1.11) Mondelez MDLZ 0.46 vs 0.44 Southern SO (0.71 vs 0.74) Time Warner TWX (1.19 vs 1.29) Veritiv VRTV 0.93 Vulcan Mat VMC 1.21 v 0.90</p> <p>07:00 hrs MBA Mortgage Applications Index 07/29 (NA vs 0.4%) 08:15 hrs ADP Employment Change July (187K vs 158K) 10:30 hrs Crude Inventories 07/29 (NA vs -7.2Mln Bbls)</p> <p>American Int'l AIG (1.20 vs 0.98) CenturyLink CTL 0.49 vs 0.63 Chemours CC 0.85 vs 0.27</p>
THURSDAY	<p>Aetna AET 2.35 vs 2.21 Allergan AGN 3.92 vs 3.35 AmerisourceBergen ABC 1.38 vs 1.37 Arrow Elec ARW 1.77 vs 1.65 Avon AVP 0.07 vs 0.07 CDW 1.02 vs 0.93 Canadian Nat Resources CNQ 0.23 vs 0.16 Church and Dwight CHD 0.39 vs 0.85 CLX 1.49 v1.30</p> <p>07:30 hrs Challenger Job Cuts July (NA vs -19.3%) 08:30 hrs Initial Claims 07/29 (242K vs 244K) 08:30 hrs Continuing Claims 07/22 (NA vs 1964K) 10:00 hrs Factory Orders June (+2.9% vs -0.8%) 10:00 hrs ISM Services July (56.9 vs 57.4) 10:30 hrs Natural Gas Inventories 07/29(NA vs 17 bcf)</p> <p>Activision Blizzard ATVI 0.30 vs 0.45 Alleghany Corp Y 7.95 vs 4.99 Fluor FLR 0.59 v 0.72</p>
FRIDAY	<p>Aon AON 1.44 vs 1.39 CIGNA CI 2.48 vs 1.98 Cooper Tire CTB 0.74 vs 1.27 Newell NWL (0.87 vs 0.78) Toyota TM (153 vs 91) Well-Care WCG 2.24 vs 2.23</p> <p>08:30 hrs Nonfarm Payrolls July (181K vs 222K) 08:30 hrs Nonfarm Private Payrolls July (175K vs 187K) 08:30 hrs Unemployment Rate July (4.3% vs 4.4%) 08:30 hrs Avg Hourly Earnings July (0.3% vs 0.2%) 08:30 hrs Average Workweek July (34.5hrs vs 34.5hrs) 08:30 hrs Trade Balance June (-44.9B vs -\$46.5B)</p> <p>The U.S. Oil Rig Count decreased by 1 Rig to 765. The Nat Gas Rig count decreased by 3 to a total of 189, making a total rig count 954. Crude closed lower at \$49.06 vs \$49.19 or -0.26%.</p> <p>Natural Gas closed the week falling \$ 0.026 or -0.9% at \$ 2.94.</p>

FUNDAMENTALS

The Dow Jones Industrials (22,092.81+262.50 or +1.2%) led all indexes again for the week, duplicating its performance of the previous week making it +2.4% for the past two weeks. The Dow has strung together nine consecutive up days gaining 579.64 points making new all-time highs. Leading the way Apple (AAPL: \$156.39) + \$6.89 or + 4.6% and 3M Company (MMM: \$ 207.65) + \$7.93 or + 4.0% Other outperformers included United Health Group (UNH: \$ 194.88) + \$ 3.73 or + 2%; Pfizer (PFE: \$ 33.64) + \$0.49 or + 1.5% and Johnson & Johnson (JNJ: \$133.18) + \$1.33 or +1%.

The S&P 500 (2476.83) + \$ 4.73 or + 0.19% was the other index closing with gains for the week, even though after reaching 2480, being overbought and unable to accelerate, it just hovered sideways.

The Nasdaq Composite (6351.56) -\$ 23.11 or - 0.36% had a small loss of less than a percent for the first week in August after gaining 3.4% in July. 6250 is major support, while it can't seem to claim the 13 day moving average at 6390. The QQQ has support at 140.80. Over 144 it looks good.

The Dow Jones Transportation Average (9277.63) + \$50.56 or + 0.55% was the second best performing index last week. Minor support is at 90.50, while resistance hovers at 94.50.

Index	Started Week	Ended Week	Change	% Change	YTD %
DJIA	21830.31	22092.81	262.50	1.2%	11.8
Nasdaq	6374.68	6351.56	-23.12	-0.4%	18.0
S&P 500	2472.10	2476.83	4.73	0.2%	10.6
Russell 2000	1429.26	1412.32	-16.94	-1.2%	4.1
DJT	9471.27	9277.63	+50.56	+0.5%	2.0

US Dollar (DXYO: 93.49) +\$0.23 or + 0.25%. The dollar collapsed to its lowest level since June 2016. The weak greenback is bullish for exports. The greenback has major support \$90, the 200 day moving average.

Volatility (VIX: \$10.03 -\$ 0.26 or - 2.5%) Volatility is looking for support, declining in a bullish stock market scenario.

CBOE OEX Volatility Index (VXO-X 8.90) + \$ 0.64 or +7.7% after making a new all-time low at 6.32, on July 25th, the index reversed closing to the 50 day moving average at about \$ 9.10. A close is needed above the \$ 9.10 area to signal a possible top in stocks. Equities benefit from low volatility.

The UVXY, (\$ 29.79) or - \$ 0.40 (4 for 1 equivalent) for the old shares, has major resistance at \$ 33-34, which is close to the 50 day price moving average. It needs to close higher to signal a decline in stocks.

The U.S. Oil Fund (USO: \$10.13) -0.04 or about flat consolidating its gains from an oversold market. Oil exploration in the U.S. is up 100.8% and gas exploration is up 133%. Spot oil prices are up 21.2% from last year while natural gas prices are up 2.5%.

Semiconductors (SMH: \$ 85.69) -0.66 or -0.8% : The 85.50 level is approximately the 50 day moving average and an important level that must hold if this bull market is to continue. The action looks topy.

Gold (GLD: \$119.65 -\$1.04 or -0.86% Found support at the \$114.80 level and then rallied impressively to close above the 200 day moving average at \$118.

The GDX, the VanEck Gold Miners ETF (GDX: 22.32) - \$0.59or -2.6% Found support at a double bottom at the \$21.00 level, and on August 1st approached resistance at the declining critical 200 day moving average at just above \$23.00.

Alibaba Group Holding Limited (NYSE:[BABA](#): \$53.33) -4.23 or -2.7% possibly making a double top at the \$160 level, after having rallied all year since December 30th. BABA is a market retailing leader. It rebounded nicely from oversold conditions remaining solidly bullish. Our original buy recommendation on April 11th was \$111.00/share.


Amazon (AMZN: \$ 987.58) - 42.46 or -0.3%: Climaxed at \$1083.31 and since dropped 96 points.

Crude OIL (\$49.58) -0.13 or -0.9%: Rebounded from oversold conditions with \$50 resistance. Energy stocks were oversold, but remain in a bear market supported by the overall sound economy. Look at PBF: \$ 23.40 breaking above its 200 day moving average. Also NFX @ \$26-27:

Royal Dutch Shell (RDS. A \$ 57.34) appears to be forming a bottom as it levitates toward its 50 week price moving average at about \$61.65. We would buy lower reactions in this stock to the \$52-53 level, which has excellent support at the \$50 level. September - November begins the weak seasonal for oil and could be a good time to accumulate this stock, which has consistently been a great investment for both capital gains and income.

Right now, Shell has 8.26 billion shares outstanding, and the company issued approximately 81.7 million new shares in the first half of the year to those shareholders who elected to receive their dividend in stock. Keep in mind the total cash outflow related to the dividend will be relatively lower as some shareholders will continue to elect a stock dividend over the cash dividend, but assuming all 8.26B shares will receive the cash dividend, using the \$0.47 quarterly dividend (\$1.88 per year), Shell's current total dividend commitment is approximately \$15.5B.

As this is approximately in line with the free cash flow, even throughout the more difficult times for oil producers, the dividend has been sustainable.



ECONOMICS

Productivity for the first quarter was revised up to unchanged, much better than expectations from the Briefing.com consensus of -0.2% and well above the 0.6% decline that was originally reported. Unit labor costs, meanwhile, were revised down to 2.2% on the table below. The original Briefing.com consensus was for a 2.4% increase in labor costs for the first quarter. Productivity increases have reduced labor costs significantly as illustrated on the table below, but much improved from the 6% increase in labor costs in the 2nd Qtr last year.

Both output and hours worked increased 1.7%

The unit labor cost increase was driven by a 2.2% increase in hourly compensation and no change in productivity. Unit labor costs increased 1.1% over the last four quarters.

Big Picture

The key takeaway from the report is that productivity is still weak despite the upward revision. From the first quarter of 2016 to the first quarter of 2017, productivity increased 1.2%.

Category	Q1	Q4	Q3	Q2	Q1
Nonfarm Business Sector					
Productivity Q/Q	0.0%	1.8%	3.3%	-0.1%	-0.7%
Unit Labor Costs Q/Q	2.2%	-4.6%	0.7%	6.2%	-0.3%
Productivity Y/Y	1.2%	1.1%	0.1%	-0.3%	0.0%
Unit Labor Costs Y/Y	1.1%	0.4%	3.0%	3.1%	2.4%

Nonfarm Productivity and Unit Labor Costs y/y%



Source: Bureau of Labor Statistics; updated 06/05/17

Briefing.com


Factory Orders increased 3.0% in June (Briefing.com consensus 2.9%) on the heels of an upwardly revised 0.3% decline (from -0.8%) for May. The headline increase was driven by a 19.0% increase in transportation equipment orders.

Excluding transportation, orders declined 0.2% following a 0.1% decline in May. New orders for manufactured durable goods increased 6.4% after being unchanged in May. New orders for manufactured nondurable goods declined 0.3% following a 0.6% decline in May

Total shipments decreased 0.2% following a 0.3% May increase. The inventory-to-shipments ratio increased to 1.38 from 1.37

The key takeaway from the report is that order activity outside the transportation sector was relatively weak in June. Nondefense capital goods orders, excluding aircraft -- a proxy for business spending -- were unchanged in June.

	JUN	MAY	APR	MAR	FEB
Factory Orders	3.0%	-0.3%	-0.3%	1.0%	0.8%
Less Defense	3.0%	-0.1%	-0.3%	0.4%	1.1%
Durable Goods	6.4%	0.0%	-0.8%	2.4%	1.4%
Nondurable Goods	-0.3%	-0.6%	0.2%	-0.3%	0.3%
Unfilled Factory Orders	1.3%	-0.1%	0.2%	0.3%	-0.2%
Factory Shipments	-0.2%	0.3%	0.0%	-0.2%	0.3%
Factory Inventories	0.2%	-0.2%	0.0%	0.2%	0.2%
Inventory/Shipment Ratio	1.38	1.37	1.38	1.38	1.37





Source: Census Bureau; updated 08/03/17

Briefing.com

The **Trade Balance** report for **June** showed a narrowing in the trade deficit to \$43.6 billion well below expectations of a \$ 44.8 billion deficit. The narrowing deficit was the result of June exports being \$2.4 billion more than May exports and June imports being \$0.4 billion less than May imports.

Capital goods, except automotive (+\$0.8 billion), led the export increase while industrial supplies and materials (-\$1.06 billion), pressured by a \$1.41 billion decrease in crude oil imports, drove the import decline.

The deficit with Mexico decreased \$1.2 billion to \$5.5 billion in June while the deficit with China increased \$1.2 billion to \$31.3 billion in June.




CYCLES

ETF Trades: Energy's Bounce Possibly Done

Oil's historically weak seasonality begins in the beginning of September, usually lasts until the end of November and is based upon the AMEX Oil index (XOI). The average price decline of XOI during this period over the last 15 years has been 4.7%. This trade appears to be setting up well this year although a little earlier than usual. First, MACD, stochastic and relative strength indicators applied to XOI are all on the verge of turning negative. Second, crude oil rallies off its mid-June low appears extended and on the verge of stalling. And third, inventories are still plentiful.

Aggressive traders may consider **Direxion Energy Bear 3x (ERY)** or **Pro Shares Ultra Short Oil & Gas (DUG)** to take advantage of the sectors historically weak period however, both of these funds are leveraged and volatility is magnified. An outright short position in **SPDR Energy (XLE)** is the path the Stock Trader's Analyst will take in the Almanac Investor ETF Portfolio. XLE has been trending lower since last December. Like crude oil, XLE has also enjoyed a modest bounce, but it's stochastic, relative strength and MACD indicators are all turning negative, confirming the bounce is likely over. The XLE could be shorted near resistance around \$66.70 - 67.40 or on a breakdown through the 50 day price moving average.



Although DJIA, S&P 500, NASDAQ and Russell 2000 have climbed to new all-time highs, they have only been marginally higher than their respective previous highs.

A few percentage points of potential gains have been left on the table by the Stock Trader's Almanac Tactical Seasonal Switching Strategy, although defensive positions have been holding up well. XLP, XLV, TLT, XLU, AGG and GLD all have slight to modest gains at yesterday's close. iShares Silver (SLV) has been improving lately and the loss on this position has shrunk to 2.5%. All seven of these "Worst Months" defensive positions are on Hold.

Now that the worst two consecutive month span, August to September has arrived, it would not be surprising to see the market take a breather or even pullback. Should the market pullback, then the defensive positions will likely perform their jobs better than they have during the current bull market with recent moves higher in stocks.

The STA Short trades in **SPDR Materials** (XLB), **iShares DJ Transports** (IYT), **SPDR Financials** (XLF) and **First Trust Natural Gas** (FCG) are currently all **underwater**. The biggest loss is owned by XLF, off 7.2% since being presented. XLB, IYT, XLF and FCG are all on Hold.

Last month's new ETF Trade ideas, in biotech and high-tech (IBB & IYW) have not yet traded below their respective buy limits. The buy limits are intentionally well below current levels as we would like to pick them up during any bout of weakness that could occur sometime during the next two months. IBB and IYW are only fractionally higher than one month ago so we have not missed any major break out higher. IBB and IYW can still be considered on dips below their buy limits.

The second half of July S&P 500 short trade using **Pro Shares Ultra Short S&P 500** (SDS) was never executed as **SPDR S&P 500** (SPY) did not fall below our trigger price. The SDS trade is now cancelled.

Almanac Investor ETF Portfolio									
Ticker	Exchange Traded Fund	Presented Date	Price	8/2/2017 Price	Return	Buy Limit ¹	Stop Loss ¹	Auto Sell [*]	Current Advice ¹
XLP	SPDR Consumer Staples	9/20/16	52.05	55.22	6.1%		52.99	62.06	Hold
XLV	SPDR Healthcare	9/20/16	71.10	79.53	11.9%		71.87	85.17	Hold
XLB	SPDR Materials (S)	4/4/17	53.45	54.73	-2.3%		58.80		Hold
TLT	iShares 20+ Year Bond	5/17/17	123.50	124.71	1.0%		115.25		Hold
IYT	iShares DJ Transports (S)	5/17/17	159.74	165.09	-3.2%		175.71		Hold
XLF	SPDR Financial (S)	5/17/17	23.50	25.31	-7.2%		25.85		Hold
XLU	SPDR Utilities	5/17/17	51.60	53.75	4.2%		48.70	60.22	Hold
AGG	iShares Core US Aggregate Bond	5/17/17	109.50	109.64	0.1%		98.70		Hold
SLV	iShares Silver **	5/17/17	16.07	15.67	-2.5%				Hold
GLD	SPDR Gold	5/17/17	119.50	120.40	0.8%				Hold
FCG	First Trust Natural Gas (S)	6/6/17	20.34	20.43	-0.4%		24.15		Hold
COW	iPath Bloomberg Livestock Sub-TR ETN	6/8/17	25.00	24.23	-3.1%		23.35		Hold
DBA	PowerShares DB Agriculture	6/8/17	20.03	19.89	-0.7%		18.99		Hold
IBB	iShares NASDAQ Biotech	7/6/17	277.00	317.04	Not Yet	277.00	249.30	349.49	Buy Dips
IYW	iShares US Technology	7/6/17	124.50	146.01	Not Yet	124.50	112.05	153.25	Buy Dips
SDS	ProShares UltraShort S&P 500	7/13/17	—	48.50	Cancelled				Cancelled
FXF	CurrencyShares Swiss Franc	8/3/17	97.00	97.62	New	97.00	95.25		Buy Dips
XLE	SPDR Energy (S)	8/3/17	68.07	66.36	New	68.07			Short @ resistance or break below \$64.23
Open Position Average % Return					0.3%				
Average Total % Return					2.4%				
¹ STANDARD POLICY: SELL HALF ON A DOUBLE, Buy Limits good til cancel, Stop only if closed below Stop Loss, (S) = Short Trade, *** Spilt adjusted Current Advice is based upon closing prices as they appear in table. *Auto Sell price based upon historical sector returns plus 10%. ** Average purchase price.									

August Almanac: Weak Early and Late, Brief Strength Mid-Month

Money flows from harvesting made August a great stock market month in the first half of the Twentieth Century. It was the best month from 1901 to 1951. In 1900, 37.5% of the population was farming. Now that less than 2% farm, August is amongst the worst months of the year. It is the worst DJIA and S&P 500 month from 1988-2016 with average declines of 1.3% and 1.0% respectively. August is also the worst month for NASDAQ (-0.3%), Russell 1000 (-0.9%) and Russell 2000 (-0.7%) over the same time period. In post-election years since 1953, Augusts' rankings are little changed: #12 DJIA, #11 S&P 500, #11 NASDAQ (since 1973), #11 Russell 1000 and #10 Russell 2000 (since 1981).

The first nine trading days of the month have exhibited weakness while mid-month is strongest. Note the bullish cluster from August 15-17. The end of August tends to get whacked as traders evacuate Wall Street for the summer finale. The last five days have suffered in 13 of the last 21 years with the S&P 500 up only five times on the next to last day in the past 21 years. In the last 21 years, the last five days of August have averaged losses of: Dow Jones Industrials, -1.0%; S&P 500, -0.9%; NASDAQ, -0.6% and Russell 2000, -0.02%.

On Monday of expiration the Dow has been up 15 of the last 22 times with four up more than 1%, while on expiration Friday it has been down six of the last seven years (-3.1% in 2015). Expiration week as a whole is down slightly more than half the time since 1990, but some of the losses have been steep (-2.6% in 1990, -2.3% in 1992, -4.1% in 1997, -4.0% in 2011, 2.2% in 2013 and 5.8% in 2015). The week after expiration is mildly stronger up 16 of the last 27.



The above chart is signaling seasonal bearishness for stocks. This poor seasonal performance has occurred since 1987. The Asian currency crisis and the Long-Term Capital Management hedge fund debacle ending August 31, 1998 as the DJIA fell 6.4% that day. DJIA dropped a record 1344.22 points for the month, off 15.1%, which is the second worst monthly percentage DJIA loss since 1950. Saddam Hussein triggered a 10.0% slide in August 1990. The best DJIA gains occurred in 1982 (11.5%) and 1984 (9.8%) as bear markets ended. Sizeable losses in 2010, 2011, 2013 and 2015 of over 4% on DJIA have widened Augusts' average decline.

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.46)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and the latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™ to be used with either the FREEDOM60® or the FreedomEdge® Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare** GmbH, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple™ Store and Android in the Google™ Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$10.98)

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 66.3% versus the Dow Jones +8.3%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science

divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court. Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company passed the \$ 500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 6.00*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences

entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“*PCT SPS*”).

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
 - *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
 - *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*

●and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NightFood, Inc. (NGTF 0. 15)* Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or “bites”

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, pop-corn), ice cream, chocolate candy, and cookies,

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We’ve seen it happen with low-carb, we’ve seen it happen with gluten-free. Can it happen with nighttime snacking as well?

Leo Motors (LEOM: \$ 0. 13)* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.

Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.

In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo’s power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.

Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar.

Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.

Skinvisible (SKVI: \$ 0.02)*

Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

Fundamental Analysis: Stocks To Buy with Stops: Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. As indicated on the table below, balance is critical. And we have exited most long positions. Alibaba has made a great deal of points. We are taking profits. We have no position in Alcoa AA. If long use a close below \$32 as a risk point. Flushing Financial FFIC fell to and held the 50 day price moving average on March 3rd, which was a buying opportunity. We would stay long the Flushing Financial. We have been looking for a place to buy Bristol Myers. Hecla Mining would be a speculative buy at a double bottom from July 7th at about \$ 4.82-86. We took profits on ENZ but still want to be long at lower prices. The HDGE may finally be oversold and relevant at this time. It is a decent long or offset against portfolio positions.

	Name	Business Description	PE	P/S	MV mln	Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	Largest on-line book in China; more of a retailer than Amazon	50.67	13.21	275.5B	153.33	Bought @ \$ 111 on 4/7/17 opening	Take Profits now using \$ 160 as dbl top

AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	987.58 stopped out	Sold on stop	No position
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	42.59 Stopped out 49.40	Bought 39.10 01/28/17	49.40x on June 29 th
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.54	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	26.25 Stopped out28.90 05/04	19.40 10/31/16	Looking for place to buy
BMY	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	55.95 No position	Looking for place to buy	If bought sell at 53.90x
BA	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	237.71	Long at 132 10/04/16	We would raise stops to \$210
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.00 Look for re-entry	Long at 5.30 5/5/17	A good long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3,5	592Mln	28.79	19.10 06/27/16	50 day m.a. at 27.45
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	37.42	21.15 originally bought 2/8/16	\$ 36.00 Sell short with stop at \$ 37
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	11.42	Bought at 5.13 10/7/16	<i>Sold on Opening Monday 4/3/17 Sold 8.43</i>
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	24.97	Bought at 15.42 9/30/16	23.60x stopped out on 3/21/17
HDGE	Advisor Shares	Ranger Bear ETF			Bear ETF	8.56 Starting to look good	<i>Sell stop at 8.34</i>	Must close above 8.48 to be long

Mike King
Princeton Research
3887 Pacific Street, Las Vegas, Nevada 89121

Or: Charles Moskowitz
CAM@MoneyInfo-LLC.com
617 827 1296

Phone: (702) 650-3000
Fax: (702) 697-8944

mike@princetonresearch.com or cam@princetonresearch.com
Visit: www.princetonresearch.com

Disclaimer* Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. . Princeton is paid \$ 2500 per month by Pressure Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors. Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

UNSUBSCRIBE

To unsubscribe from this newsletter, please reply to this email with UNSUBSCRIBE in the subject line. We will send you a confirmation upon completing your request.